Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children

N/ANot Yet RecruitingNCT07511387

The Hong Kong Polytechnic University40 enrolled

Overview

This study aims to evaluate the short-term efficacy and safety of a novel, proprietary spectacle lens. Forty myopic participants, aged 6 to 15 years, will be prescribed with the study spectacles for a period of six months. All subjects will be required to attend five scheduled visits. Change in subfoveal choroidal thickness (SfChT), axial length and refraction will be determined.

Optical strategies have been shown to be effective for slowing myopia progression. The design of the BLMCL patented spectacle lens is based on existing myopic control theory of peripheral defocus spectacle lenses. This prospective, observational cohort study aims to evaluate the short-term efficacy and safety of the BLMCL lens in school-aged children. Forty participants, aged 6 to 15 years with SER between -6.00D to -0.75D and astigmatism not more than -2.00D, will be fitted with the BLMCL Lens and followed for six months. They will be required to return for five scheduled visits: baseline, delivery, 1 month, 3 months, and 6 months after lens delivery visits. The primary endpoint is the change in subfoveal choroidal thickness (SfChT) for potential effective myopia control via SfChT thickening. The secondary endpoints are the changes in AL and refraction after cycloplegia which allow comparison with other myopia control studies. Subjective symptoms will be assessed using the PREP2 and QoV questionnaires.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Myopia

Interventions

BCMC lensOTHER

BLMC spectacle lens is a spectacle lens that corrects the distance refraction and provides defocus in peripheral region

Eligibility

Sex: ALLMin age: 6 YearsMax age: 15 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 6 to 15 years (Chinese), inclusive * Cycloplegic SER between -0.75 D and -6.00 D in both eyes * Astigmatism ≤ 2.00 D in both eyes * Anisometropia ≤ 1.50 D * BCVA of 0.04 logMAR or better in each eye Exclusion Criteria: * Previous or current use of any myopia control intervention within 6 months * Presence of any ocular pathology, amblyopia, colour vision deficiency or strabismus that could affect refractive development or visual function * History of ocular surgery or significant ocular trauma * Known systemic diseases or use of medications that could affect vision or ocular growth

Locations (1)

School of Optometry, The Hong Kong Polytechnic University

Hong Kong, Hong Kong

Outcomes

Primary Outcomes

Change in subfoveal choroidal thickness (SfChT)

SfChT will be measured using Swept-Source OCT (SS-OCT) without cycloplegia. It will be measured at the delivery visit before dispensing, and 1, 3 and 6 months after delivery. In order to minimize the effect of diurnal variation, it will be measured within two hours hours from the first measurement at the delivery visit. Two good quality images will be captured for each eye. Segmentation of the images will be performed by a masked examiner. Changes in SfChT after using the lenses for 1, 3, and 6 months will be determined.

Time frame: Delivery and 1, 3, and 6 months after delivery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.